Nitta Gelatin India Ltd

01Company Overview

Start with what actually arrives at the gate: bone. Nitta Gelatin buys crushed animal bone, soaks it in hydrochloric acid to strip away the mineral, and is left with a protein scaffold called ossein. Refine the ossein and you get gelatin, the stuff that makes a medicine capsule hold its shape and a dessert set. Break the gelatin into smaller pieces and you get collagen peptide, which is sold as a supplement for joints and skin. What is left of the mineral becomes dicalcium phosphate, which goes into chicken feed. Nothing is wasted, which is the point of the business. The company was set up in 1975 as a joint venture between a Japanese gelatin maker in Osaka and the Kerala state government's industrial development arm, and that unusual pairing still owns three quarters of it today. Two plants sit in Kerala, one in Maharashtra and one in Gujarat. More than 60% of production leaves the country, mostly to Japan, the United States, Canada and Europe, which makes this a small Indian exporter of a food and pharmaceutical ingredient rather than a domestic consumer story. Here is the tension you are buying. Over the last eleven years revenue went from about ₹354 crore to ₹588 crore, roughly 5% a year. Over the same stretch net profit went from a loss of ₹4 crore to ₹97 crore. Sales barely moved and profit did not, so the entire story sits in one line of the accounts: the operating margin.

02Business Model & Industry

Unit of revenue: A kilogram of purified protein. Nitta is paid for what it extracts from bone, priced against a global gelatin market it does not set.

Model: Manufacturing and sale of a processed commodity, mostly exported. No subscriptions, no contracts of any length, no recurring revenue. You make it, you ship it, you are paid.

Structure

Consolidated globally, fragmented locally. A handful of international majors set the world gelatin price; Indian processors compete below them.

Competitors

Rousselot, Gelita and PB Leiner globally. In India, Sterling Biotech historically and a set of smaller ossein processors.

Pricing power

Sits with the customer and with the global market. Nitta is a price taker at both ends, on bone in and on gelatin out.

Demand driver

Pharmaceutical capsule volumes, processed food, and the nutraceutical supplement market for the peptide. (Structural but slow. Capsules and food gelling grow with population and formalisation, not with a cycle.)

TAM

Global gelatin demand is measured in hundreds of thousands of tonnes a year and grows in low single digits. Collagen peptide is the faster-growing slice.

Penetration

Mature for gelatin. Early for collagen peptide in India, which is why the capacity going from 450 to 1,000 tonnes matters more than its 10% revenue share suggests.

Value-chain seat

Midstream. Nitta buys a waste product from meat processing and sells an ingredient to formulators. It touches no consumer and owns no brand the consumer knows.

This is a decent business trapped in a hard structure. The chemistry is real, the pharmaceutical audits are a genuine barrier, and the balance sheet is clean. The constraints are equally real. Output is limited by the bone Nitta can source and by the water and effluent permissions it holds. Price is set by a handful of global majors well above it in scale. And the two Kerala plants carry a social-licence exposure that has been contested since 2013. That is a good operator in a bad structure, which is a different thing from a good business.

03Valuation Snapshot

04Financial Performance (5Y, in Crores)

05Key Ratios

06Cash Flow Forensics (in Crores)

This is the part of the accounts that behaves. Operating cash flow of ₹122 crore in FY26 comfortably exceeded reported profit of ₹97 crore, and free cash flow has been positive in each of the last five years. Across those five years operating cash comes to about 109% of net profit, which means the margin story is showing up as actual money rather than as receivables. FY26 was also the first serious spending year in a decade. Purchases of fixed assets came to about ₹50 crore against depreciation of ₹16 crore, and the whole investing line shows an outflow of roughly ₹182 crore. Those are not the same number: the larger figure includes deposits and investments made with the cash pile alongside the plant spending, so treat ₹50 crore as the capex and the rest as the treasury. Either way, a business that has not needed capital for years has started using it.

06.1What the margin is worth

07Growth

08Management

The company is run under a joint-venture structure that is genuinely unusual for a listed Indian small-cap. Nitta Gelatin Inc of Osaka, a gelatin specialist with its own global customer base, sits on one side; the Kerala State Industrial Development Corporation, the state government's investment arm, sits on the other. Together they hold 74.49%, and that holding has not moved by a single basis point across the last six reported quarters. Judge them on what they did with the cash rather than on what they say. Borrowings came down from ₹109 crore in FY17 to ₹4 crore in FY26, funded from operations with no equity issued: share capital has been ₹9 crore for eleven straight years, so nobody has been diluted. Then, having cleared the debt, they spent. FY26 carries about ₹50 crore of fixed-asset purchases against depreciation of ₹16 crore, going into gelatin capacity and into more than doubling the collagen peptide line. The wider investing outflow of roughly ₹182 crore also covers deposits and investments made with the cash pile, so the two figures should not be read as the same thing. That is a patient, conventional sequence: fix the balance sheet first, then build. The reservation is about incentive rather than competence. A Japanese industrial parent wants reliable supply of audited gelatin. A state development corporation wants employment in Kerala. Neither objective requires the share price to be higher, and a dividend payout of 7% of profit is consistent with that. This is a well-run company. It is not run for the minority shareholder.

09Shareholding

10Moat

• Pharmaceutical-grade approvals and audits in Japan, the United States and Europe
• A Japanese parent whose customer relationships come with the joint venture
• Fifty years of process knowledge in a chemistry that is fussy and unglamorous
• Bone sourcing relationships, which are local, relationship-led and not easy to assemble quickly

The moat is real and it is small. What protects Nitta is that a pharmaceutical customer cannot switch gelatin suppliers casually: the new supplier has to pass the same audits, prove the same traceability on where the bone came from, and do it without interrupting a capsule line. That is a genuine switching cost and it explains why a company this size sells into Japan and the United States at all. What the moat cannot do is set a price. Gelatin is a global commodity with a handful of large producers above Nitta in scale, and the FY26 experience proved the point: exports fell because American tariffs made customers cautious, and there was nothing Nitta could do about it. So the audit trail keeps rivals out of its customers. It does nothing at all about the spread between bone and gelatin, which is where all the money is.

11The Story So Far

For most of its listed life this was a dull, marginal business. From FY15 to FY21 revenue went from ₹354 crore to ₹396 crore and the operating margin sat between 7% and 11%, which on this asset base produced a return on capital of 6% to 12%. It carried around ₹100 crore of debt and earned barely enough to service it comfortably. Then something changed. In FY23 the operating margin jumped to 20% and profit more than doubled to ₹74 crore. FY24 pushed margin to 23%. Revenue, meanwhile, did almost nothing: ₹565 crore in FY23, ₹533 crore in FY24, ₹527 crore in FY25, ₹588 crore in FY26. The debt was cleared along the way, funded from operations. Then FY26 broke the pattern in a second way: after a decade of spending only what depreciation required, the company put real money into capacity, and collagen peptide exports doubled on American demand while gelatin exports fell on US tariff uncertainty. The stock has followed the profit and then some, up about 98% in the last year and compounding at 47% a year over five against 41% profit growth over the same window.

12Risks

13What the Headline Numbers Hide

Sector checklist

14Two-Engine Assessment

15Mental-Model Lenses

16Outlook: What Happens Next?

17Summary

Nitta Gelatin turns crushed bone into pharmaceutical gelatin, and does it well enough that Japanese and American customers buy from a ₹1,517 crore company in Kerala. The balance sheet is effectively debt free, profit turns into cash, and return on capital is 28%. What the accounts cannot tell you is whether a 24% operating margin is the new normal for a business that operated on 10% for its first four decades. That single number decides the valuation, and the sensitivity table above prices it: cheap at 24%, ordinary at 18%, expensive below 15% unless revenue starts growing. Which is why FY26 matters beyond its profit figure. It is the first year in a decade that management spent on capacity rather than on debt, and the collagen peptide expansion is the only route to growth that does not depend on the margin holding.